PL2061485T3 - Peptydy EV576 do zastosowania w leczeniu zespołu Guillaina-Barrégo - Google Patents

Peptydy EV576 do zastosowania w leczeniu zespołu Guillaina-Barrégo

Info

Publication number
PL2061485T3
PL2061485T3 PL07804199T PL07804199T PL2061485T3 PL 2061485 T3 PL2061485 T3 PL 2061485T3 PL 07804199 T PL07804199 T PL 07804199T PL 07804199 T PL07804199 T PL 07804199T PL 2061485 T3 PL2061485 T3 PL 2061485T3
Authority
PL
Poland
Prior art keywords
peptides
treatment
barré syndrome
guillain barré
guillain
Prior art date
Application number
PL07804199T
Other languages
English (en)
Inventor
John Hamer
Original Assignee
Volution Immuno Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals Sa filed Critical Volution Immuno Pharmaceuticals Sa
Publication of PL2061485T3 publication Critical patent/PL2061485T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07804199T 2006-09-08 2007-09-10 Peptydy EV576 do zastosowania w leczeniu zespołu Guillaina-Barrégo PL2061485T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0617734.9A GB0617734D0 (en) 2006-09-08 2006-09-08 Method of treating peripheral nerve disorders
EP07804199A EP2061485B1 (en) 2006-09-08 2007-09-10 EV576 peptides for use in the treatment of Guillain Barré syndrome
PCT/GB2007/003401 WO2008029167A1 (en) 2006-09-08 2007-09-10 Method of treating peripheral nerve disorders

Publications (1)

Publication Number Publication Date
PL2061485T3 true PL2061485T3 (pl) 2013-03-29

Family

ID=37232629

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07804199T PL2061485T3 (pl) 2006-09-08 2007-09-10 Peptydy EV576 do zastosowania w leczeniu zespołu Guillaina-Barrégo

Country Status (11)

Country Link
US (4) US9211312B2 (pl)
EP (1) EP2061485B1 (pl)
JP (1) JP5557528B2 (pl)
AU (1) AU2007293239B2 (pl)
CA (1) CA2662715C (pl)
DK (1) DK2061485T3 (pl)
ES (1) ES2397900T3 (pl)
GB (1) GB0617734D0 (pl)
NZ (1) NZ575461A (pl)
PL (1) PL2061485T3 (pl)
WO (1) WO2008029167A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
PT3028716T (pt) * 2006-10-10 2020-11-23 Regenesance B V Inibição do complemento para regeneração nervosa melhorada
JP5840623B2 (ja) 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
DK2817329T3 (en) 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polypeptides Binding to Human Complement Component C5.
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CA2988313A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
AU2017283470B2 (en) 2016-06-14 2024-03-21 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies and uses thereof
EP4272821A3 (en) 2017-04-03 2024-01-03 InflaRx GmbH Treatment of inflammatory diseases with inhibitors of c5a activity
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
PL3612208T3 (pl) 2017-04-21 2023-07-24 Volution Immuno Pharmaceuticals Sa Coversin do leczenia autoimmunologicznych chorób pęcherzowych
CA3066689C (en) 2017-06-23 2024-01-16 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity
JP2021506241A (ja) 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃ５抗体組み合わせ物およびその使用
EP3849588A1 (en) 2018-09-10 2021-07-21 Volution Immuno Pharmaceuticals SA Coversin for use in the treatment of rheumatic diseases
GB201905810D0 (en) 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
WO2021058117A1 (en) 2019-09-27 2021-04-01 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (hsct-tma)
AU2020438234A1 (en) 2020-03-27 2022-09-29 Inflarx Gmbh Inhibitors of C5a for the treatment of corona virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1476469B1 (en) * 2002-01-25 2015-11-18 Novo Nordisk A/S Monoclonal antibodies against extracellular loops of c5ar
ITMI20021527A1 (it) * 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
BRPI0410876B8 (pt) * 2003-06-02 2023-01-24 Evolutec Ltd composição, proteína de fusão, molécula de cdna, vetor, célula hospedeira procariótica recombinante, método para preparar uma molécula inibidora do complemento, e, usos de uma composição e de uma proteína de fusão
CA2579635A1 (en) * 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
AU2007293013B2 (en) 2006-09-05 2013-06-27 Alexion Pharmaceuticals, Inc. Method and compositions for the treatment of antibody mediated neuropathies
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders

Also Published As

Publication number Publication date
DK2061485T3 (da) 2012-11-19
US20100111929A1 (en) 2010-05-06
NZ575461A (en) 2011-11-25
GB0617734D0 (en) 2006-10-18
JP2010502686A (ja) 2010-01-28
CA2662715C (en) 2018-04-03
JP5557528B2 (ja) 2014-07-23
AU2007293239A1 (en) 2008-03-13
CA2662715A1 (en) 2008-03-13
WO2008029167A1 (en) 2008-03-13
ES2397900T3 (es) 2013-03-12
US9211312B2 (en) 2015-12-15
EP2061485A1 (en) 2009-05-27
EP2061485B1 (en) 2012-08-22
US20220249608A1 (en) 2022-08-11
US20190117730A1 (en) 2019-04-25
AU2007293239B2 (en) 2012-07-05
US20160166641A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
PL2061485T3 (pl) Peptydy EV576 do zastosowania w leczeniu zespołu Guillaina-Barrégo
HUE048024T2 (hu) Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
HK1252316A1 (zh) IL-1β抗體的用途
ZA200800464B (en) Peptides for use in the treatment of obesity
EP2054521A4 (en) METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
IL192159A0 (en) Nanoclusters for delivery of the therapeutics
HRP20130109T1 (en) Caspofungin formulations
EP2032156A4 (en) COMPOSITIONS AND METHOD FOR THE DELIVERY OF OXYGEN
PT2152290E (pt) Métodos para administrar anticorpos anti-il-5
EP2054042A4 (en) METHODS FOR PREPARING BIOLOGICALLY ACTIVE COMPOUNDS IN THE FORM OF NANOPARTICLES
ZA200808409B (en) Use of rasagiline for the treatment of restless legs syndrome
IL194202A0 (en) Treatment using citrulline
IL192373A (en) Arginine cyclic peptides and their use in the treatment of fungal infections
SI2054088T1 (sl) Naprava za obdelavo vsebnikov
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
GB0722996D0 (en) Depsipeptides and their therapeutic use
GB2443933B (en) Vapour delivering device
GB0609121D0 (en) Peptide Therapy
ZA200806949B (en) Medicinal formulation for the treatment for hepatitis C
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
GB0403808D0 (en) Films for use as dosage forms
HK1138189A1 (en) Use of a compound in the manufacture of a medicament for the treatment of leukaemia
TWI370735B (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
GB0625671D0 (en) Protein formulation
HK1125634A1 (en) Pharmaceutical for use in the treatment of ureterolithiasis